Iovance Biotherapeutics I... (IOVA)
NASDAQ: IOVA
· Real-Time Price · USD
2.30
0.03 (1.32%)
At close: Sep 16, 2025, 3:59 PM
2.30
-0.06%
Pre-market: Sep 17, 2025, 08:09 AM EDT
1.32% (1D)
| Bid | 2.3 |
| Market Cap | 832.26M |
| Revenue (ttm) | 241.52M |
| Net Income (ttm) | -389.92M |
| EPS (ttm) | -1.21 |
| PE Ratio (ttm) | -1.9 |
| Forward PE | -3.6 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 2.38 |
| Volume | 9,039,653 |
| Avg. Volume (20D) | 16,549,862 |
| Open | 2.26 |
| Previous Close | 2.27 |
| Day's Range | 2.24 - 2.38 |
| 52-Week Range | 1.64 - 12.51 |
| Beta | 0.82 |
| Ex-Dividend Date | n/a |
About IOVA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IOVA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IOVA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsIovance Biotherapeutics Inc. is scheduled to release its earnings on
Nov 6, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 weeks ago
+4%
Iovance Biotherapeutics shares are trading higher ...
Unlock content with
Pro Subscription
1 month ago
-20.08%
Iovance Biotherapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results and issued FY25 sales guidance below estimates. Additionally, Chardan Capital reduced its price target on the stock from $25 to $20.
3 weeks ago · seekingalpha.com
Iovance Biotherapeutics: Tough Decisions Being Made But Catalysts In H2'25IOVA's Amtagvi (lifileucel) launch shows progress with Q2'25 revenue growth, helping rebuild confidence after prior stagnation. Cash burn remains a concern, but the company announced a restructuring w...
